These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 26231159)
21. Identification of Moslin R; Zhang Y; Wrobleski ST; Lin S; Mertzman M; Spergel S; Tokarski JS; Strnad J; Gillooly K; McIntyre KW; Zupa-Fernandez A; Cheng L; Sun H; Chaudhry C; Huang C; D'Arienzo C; Heimrich E; Yang X; Muckelbauer JK; Chang C; Tredup J; Mulligan D; Xie D; Aranibar N; Chiney M; Burke JR; Lombardo L; Carter PH; Weinstein DS J Med Chem; 2019 Oct; 62(20):8953-8972. PubMed ID: 31314518 [TBL] [Abstract][Full Text] [Related]
22. Discovery of 3-(4-(2-((1 Zhang C; Qi W; Li Y; Tang M; Yang T; Liu K; Chen Y; Deng D; Xiang M; Chen L J Med Chem; 2021 Feb; 64(4):1966-1988. PubMed ID: 33593051 [TBL] [Abstract][Full Text] [Related]
23. Synthesis and biological evaluation of pyrrolopyridazine derivatives as novel HER-2 tyrosine kinase inhibitors. Tang PC; Feng J; Huang L; Xu Z; Cheng L; Zhang X; Zhang L; Hu B Bioorg Med Chem Lett; 2009 Nov; 19(22):6437-40. PubMed ID: 19815412 [TBL] [Abstract][Full Text] [Related]
24. Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165. Wrobleski ST; Moslin R; Lin S; Zhang Y; Spergel S; Kempson J; Tokarski JS; Strnad J; Zupa-Fernandez A; Cheng L; Shuster D; Gillooly K; Yang X; Heimrich E; McIntyre KW; Chaudhry C; Khan J; Ruzanov M; Tredup J; Mulligan D; Xie D; Sun H; Huang C; D'Arienzo C; Aranibar N; Chiney M; Chimalakonda A; Pitts WJ; Lombardo L; Carter PH; Burke JR; Weinstein DS J Med Chem; 2019 Oct; 62(20):8973-8995. PubMed ID: 31318208 [TBL] [Abstract][Full Text] [Related]
25. Discovery of GLPG3667, a Selective ATP Competitive Tyrosine Kinase 2 Inhibitor for the Treatment of Autoimmune Diseases. Mammoliti O; Martina S; Claes P; Coti G; Blanque R; Jagerschmidt C; Shoji K; Borgonovi M; De Vos S; Marsais F; Oste L; Quinton E; López-Ramos M; Amantini D; Brys R; Jimenez JM; Galien R; van der Plas S J Med Chem; 2024 Jun; 67(11):8545-8568. PubMed ID: 38805213 [TBL] [Abstract][Full Text] [Related]
26. Lead optimization of a 4-aminopyridine benzamide scaffold to identify potent, selective, and orally bioavailable TYK2 inhibitors. Liang J; van Abbema A; Balazs M; Barrett K; Berezhkovsky L; Blair W; Chang C; Delarosa D; DeVoss J; Driscoll J; Eigenbrot C; Ghilardi N; Gibbons P; Halladay J; Johnson A; Kohli PB; Lai Y; Liu Y; Lyssikatos J; Mantik P; Menghrajani K; Murray J; Peng I; Sambrone A; Shia S; Shin Y; Smith J; Sohn S; Tsui V; Ultsch M; Wu LC; Xiao Y; Yang W; Young J; Zhang B; Zhu BY; Magnuson S J Med Chem; 2013 Jun; 56(11):4521-36. PubMed ID: 23668484 [TBL] [Abstract][Full Text] [Related]
27. A new regulatory switch in a JAK protein kinase. Tsui V; Gibbons P; Ultsch M; Mortara K; Chang C; Blair W; Pulk R; Stanley M; Starovasnik M; Williams D; Lamers M; Leonard P; Magnuson S; Liang J; Eigenbrot C Proteins; 2011 Feb; 79(2):393-401. PubMed ID: 21117080 [TBL] [Abstract][Full Text] [Related]
28. Structure-based design and development of (benz)imidazole pyridones as JAK1-selective kinase inhibitors. Simov V; Deshmukh SV; Dinsmore CJ; Elwood F; Fernandez RB; Garcia Y; Gibeau C; Gunaydin H; Jung J; Katz JD; Kraybill B; Lapointe B; Patel SB; Siu T; Su H; Young JR Bioorg Med Chem Lett; 2016 Apr; 26(7):1803-8. PubMed ID: 26927423 [TBL] [Abstract][Full Text] [Related]
29. Design, Synthesis and Activity Study of Pyridine Derivatives as Highly Effective and Selective TYK2 Inhibitors. Cheng C; Zhou M; Zhang P; Qian W; Chen L; Chen G Biomed Res Int; 2022; 2022():6383893. PubMed ID: 35586808 [TBL] [Abstract][Full Text] [Related]
30. Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841). Fensome A; Ambler CM; Arnold E; Banker ME; Brown MF; Chrencik J; Clark JD; Dowty ME; Efremov IV; Flick A; Gerstenberger BS; Gopalsamy A; Hayward MM; Hegen M; Hollingshead BD; Jussif J; Knafels JD; Limburg DC; Lin D; Lin TH; Pierce BS; Saiah E; Sharma R; Symanowicz PT; Telliez JB; Trujillo JI; Vajdos FF; Vincent F; Wan ZK; Xing L; Yang X; Yang X; Zhang L J Med Chem; 2018 Oct; 61(19):8597-8612. PubMed ID: 30113844 [TBL] [Abstract][Full Text] [Related]
31. Toward selective TYK2 inhibitors as therapeutic agents for the treatment of inflammatory diseases. Menet CJ Pharm Pat Anal; 2014 Jul; 3(4):449-66. PubMed ID: 25291316 [TBL] [Abstract][Full Text] [Related]
32. A Dual Inhibition, a Better Solution: Development of a JAK1/TYK2 inhibitor. Menet CJ J Med Chem; 2018 Oct; 61(19):8594-8596. PubMed ID: 30252456 [No Abstract] [Full Text] [Related]
33. Tyk2 tyrosine kinase expression is required for the maintenance of mitochondrial respiration in primary pro-B lymphocytes. Potla R; Koeck T; Wegrzyn J; Cherukuri S; Shimoda K; Baker DP; Wolfman J; Planchon SM; Esposito C; Hoit B; Dulak J; Wolfman A; Stuehr D; Larner AC Mol Cell Biol; 2006 Nov; 26(22):8562-71. PubMed ID: 16982690 [TBL] [Abstract][Full Text] [Related]
34. Commentary on H. Ide et al., "Tyk2 expression and its signaling enhances the invasiveness of prostate cancer cells". Schuster C; Müller M; Freissmuth M; Sexl V; Stoiber D Biochem Biophys Res Commun; 2008 Feb; 366(4):869-70. PubMed ID: 18082134 [No Abstract] [Full Text] [Related]
35. Anti-leukaemic activity of the TYK2 selective inhibitor NDI-031301 in T-cell acute lymphoblastic leukaemia. Akahane K; Li Z; Etchin J; Berezovskaya A; Gjini E; Masse CE; Miao W; Rocnik J; Kapeller R; Greenwood JR; Tiv H; Sanda T; Weinstock DM; Look AT Br J Haematol; 2017 Apr; 177(2):271-282. PubMed ID: 28295194 [TBL] [Abstract][Full Text] [Related]
36. Discovery of a potent and subtype-selective TYK2 degrader based on an allosteric TYK2 inhibitor. Kato JY; Korenaga S; Iwakura M Bioorg Med Chem Lett; 2023 Jan; 79():129083. PubMed ID: 36414177 [TBL] [Abstract][Full Text] [Related]
37. Entry into a new class of protein kinase inhibitors by pseudo ring design. Furet P; Caravatti G; Guagnano V; Lang M; Meyer T; Schoepfer J Bioorg Med Chem Lett; 2008 Feb; 18(3):897-900. PubMed ID: 18248988 [TBL] [Abstract][Full Text] [Related]
38. Lead optimization and structure-based design of potent and bioavailable deoxycytidine kinase inhibitors. Jessop TC; Tarver JE; Carlsen M; Xu A; Healy JP; Heim-Riether A; Fu Q; Taylor JA; Augeri DJ; Shen M; Stouch TR; Swanson RV; Tari LW; Hunter M; Hoffman I; Keyes PE; Yu XC; Miranda M; Liu Q; Swaffield JC; David Kimball S; Nouraldeen A; Wilson AG; Foushee AM; Jhaver K; Finch R; Anderson S; Oravecz T; Carson KG Bioorg Med Chem Lett; 2009 Dec; 19(23):6784-7. PubMed ID: 19836232 [TBL] [Abstract][Full Text] [Related]
39. Tyrosine kinase 2 interacts with the proapoptotic protein Siva-1 and augments its apoptotic functions. Shimoda HK; Shide K; Kameda T; Matsunaga T; Shimoda K Biochem Biophys Res Commun; 2010 Sep; 400(2):252-7. PubMed ID: 20727854 [TBL] [Abstract][Full Text] [Related]
40. TYK2, a Candidate Gene for Type 1 Diabetes, Modulates Apoptosis and the Innate Immune Response in Human Pancreatic β-Cells. Marroqui L; Dos Santos RS; Fløyel T; Grieco FA; Santin I; Op de Beeck A; Marselli L; Marchetti P; Pociot F; Eizirik DL Diabetes; 2015 Nov; 64(11):3808-17. PubMed ID: 26239055 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]